
|Articles|December 1, 2004
New Products & Services
Raritan, NJ-The FDA has approved a once-a-day liquid formulation of the fluoroquinone antibiotic levofloxacin (Levaquin), from Ortho-McNeil Pharmaceutical, Inc. Levofloxacin is indicated for the treatment of a number of infections, including complicated and uncomplicated urinary tract infections, chronic bacterial prostatitis, and acute pyelonephritis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
5











